Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas

Sao Paulo Medical Journal

Volumn 126, Issue 1, 2008, Pages 63-66

  Fabrício, Vanessa de Carvalho ^a,b   Amado, Fernanda ^c   Del Giglio, Auro ^a,d,e  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b Hospital Estadual Mário Covas ^*  (Brazil)

^c Centro de Reabilitação do Hospital Estadual Mário Covas   (Brazil)

^d HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^e AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

Antineoplastic combined chemotherapy protocols; Esophageal neoplasms; Head and neck neoplasms; Quality of life karnofsky performance status

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BRAZIL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG COST; ESOPHAGUS CARCINOMA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HEALTH STATUS; HUMAN; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 44649125032     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802008000100012     Document Type: Article

References (19)

1. Gebbia V, Tesra A, Valenza R, et al. A phase II study of levofolinic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma. Oncology. 1993;50(6):490-4.
2. Lee JJ, Jeng JH, Wang HM, et al. Univariate and multivariate analysis of prognostic significance of betel quid chewing in squamous cell carcinoma of buccal mucosa in Taiwan. J Surg Oncol. 2005;91(1):41-7.
3. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949-55.
4. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Aphm III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521-6.
5. Colevas, AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24(17):2644-52.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
7. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990;65(8):1864-6.
8. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogenoeus diagnosis. Qual Life Res. 1993;2(2):129-40.
9. Souza RCC, Barros CAA, Souza RRL, et al. Avaliação da qualidade de vida de doentes de carcinoma retal, submetidos à ressecção com preservação esfincteriana ou à amputação abdǒmino-perineal. [Evaluation of life quality of sick people of rectal carcinoma, submitted to the resection with sphincter preservation or the abdominoperineal amputation. Rev Bras Colo-proctol. 2005;25(3):235-40.
10. Samano ES, Goldenstein PT, Ribeito Lde M, et al. Praying correlates with higher quality of life: results from a survey on complementary/ alternative medicine use among a group of Brazilian cancer patients. Sao Parulo Med J. 2004;122(2):60-3.
11. National Cancer Institute CTC v2.0 and Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://crep.cancer.gov/ reporting/ctc.html. Accessed in 2007 (Nov 27).
12. Olmi P, Crispino, S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy-a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(1):78-92.
13. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22(1):69-76.
14. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced had and neck carcinomas radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005;23(13):3008-15.
15. Zorat PL, Paccagnella A, Cavaniglia G, et al. Ramdomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004;96(22):1714-17.
16. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890-900.
17. Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol. 2006;24(17):2653-8.
18. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15(1):261-7.
19. Vokes EE, Schilsky RL, Weichselbaum RR, et al. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989;63(6 Suppl): 1048-53.